These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32331932)

  • 21. [Alarm clock for dormant HI viruses].
    MMW Fortschr Med; 2014 Oct; 156(17):32. PubMed ID: 25417463
    [No Abstract]   [Full Text] [Related]  

  • 22. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells.
    Lin S; Zhang Y; Ying H; Zhu H
    Curr HIV Res; 2011 Jun; 9(4):202-8. PubMed ID: 21631428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products.
    Richard K; Williams DE; de Silva ED; Brockman MA; Brumme ZL; Andersen RJ; Tietjen I
    Viruses; 2018 Jun; 10(7):. PubMed ID: 29954099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV latency reversal agents: A potential path for functional cure?
    Lopes JR; Chiba DE; Dos Santos JL
    Eur J Med Chem; 2021 Mar; 213():113213. PubMed ID: 33540228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors That Potently Reactivate Latent HIV.
    Curreli F; Ahmed S; Victor SMB; Debnath AK
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32503121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
    Martínez-Bonet M; Clemente MI; Serramía MJ; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Sci Rep; 2015 Nov; 5():16445. PubMed ID: 26563568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
    Gong CJ; Gao AH; Zhang YM; Su MB; Chen F; Sheng L; Zhou YB; Li JY; Li J; Nan FJ
    Eur J Med Chem; 2016 Apr; 112():81-90. PubMed ID: 26890114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor.
    Lim H; Kim KC; Son J; Shin Y; Yoon CH; Kang C; Choi BS
    Virus Res; 2017 Jan; 227():1-5. PubMed ID: 27677464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.
    Savarino A; Mai A; Norelli S; El Daker S; Valente S; Rotili D; Altucci L; Palamara AT; Garaci E
    Retrovirology; 2009 Jun; 6():52. PubMed ID: 19486542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.
    Gray LR; On H; Roberts E; Lu HK; Moso MA; Raison JA; Papaioannou C; Cheng WJ; Ellett AM; Jacobson JC; Purcell DF; Wesselingh SL; Gorry PR; Lewin SR; Churchill MJ
    J Neurovirol; 2016 Aug; 22(4):455-63. PubMed ID: 26727904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
    Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
    Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
    Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
    Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
    Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
    Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
    EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.
    Garcia-Vidal E; Badia R; Pujantell M; Castellví M; Felip E; Clotet B; Riveira-Muñoz E; Ballana E; Esté JA
    Antiviral Res; 2019 Aug; 168():18-27. PubMed ID: 31077767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
    Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
    EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.